Kimberly Rieger | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Kimberly Rieger
Lahey Clinic, United States

              Kimberly Rieger
Affiliation Lahey Clinic
Country United States
Scopus ID 6602699362
Documents 87
Citations 15,323
h-index 33
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-8425

Kimberly Rieger is a cancer researcher associated with Lahey Clinic and the Cell and Molecular Biology research environment at Lahey Hospital & Medical Center. Her published work spans molecular oncology, cancer biology, microRNA regulation, tumor progression, biomarkers, and mechanisms associated with treatment response. [1]

Abstract

The Innovative Research Award profile recognizes Kimberly Rieger-Christ in the context of cancer cell biology and translational oncology research. Her research record includes studies examining molecular regulators of tumor behavior, microRNA-associated pathways, cancer biomarkers, metastatic phenotypes, and mechanisms influencing treatment response. [3] Such research contributes to understanding how molecular alterations can influence cancer progression and clinical outcomes.

Keywords

Cancer Cell Biology; Cancer Research; Molecular Oncology; MicroRNA; Bladder Cancer; Renal Cell Carcinoma; Lung Cancer; Biomarkers; Tumor Progression; Metastasis; Treatment Resistance; Translational Research; Molecular Diagnostics; Oncology.

Introduction

Cancer cell biology investigates the molecular and cellular processes that regulate malignant transformation, proliferation, invasion, metastasis, and response to therapy. Within this field, microRNAs and other regulatory molecules are important because they can influence multiple genes and signaling pathways simultaneously. Rieger-Christ’s published research has addressed these mechanisms across several cancer contexts, particularly urologic malignancies. [5]

Research Profile

The available research record places Rieger-Christ within a multidisciplinary cancer research environment involving molecular biology, genetics, gene expression, cell signaling, and cancer genomics. Her work has included experimental and translational studies addressing bladder cancer, renal cell carcinoma, prostate cancer, and lung cancer.Institutional sources describe research interests that include the molecular basis of genitourinary cancers and the development of improved approaches for diagnosis, prevention, and treatment. [2]

Research Contributions

A recurring contribution in the research record is investigation of microRNA biology in cancer. Published work has examined microRNA profiles associated with gemcitabine resistance in bladder carcinoma cell lines and microRNA signatures associated with invasive disease. [3] These studies address mechanisms that may help explain differences in tumor behavior and therapeutic response.

Publications

Selected publications associated with Kimberly Rieger-Christ demonstrate a sustained focus on molecular oncology. Her work includes studies of microRNA-mediated regulation, cancer invasion, treatment resistance, and molecular characteristics of tumor progression. The Lahey research publication archive records multiple contributions across these areas and provides DOI information for several publications. [3]

  • Kozinn et al. (2013), “MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.”
  • Das et al. (2023), “The Roles of MiRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.”
  • Kalantzakos et al. (2023), “MicroRNA-155-5p Targets JADE-1, Promoting Proliferation, Migration, and Invasion in Clear Cell Renal Cell Carcinoma Cells.”

Research Impact

Research impact in cancer biology can be assessed through publication continuity, citation activity, methodological relevance, and contribution to clinically meaningful scientific questions. The supplied profile records 87 documents, 15,323 citations, and an h-index of 33. These figures are presented as the profile information supplied for this recognition page and may change as bibliographic databases are updated.The scientific relevance of the work is also reflected in its connection to cancer recurrence, treatment resistance, invasion, metastasis, and biomarker development. . [2]

Award Suitability

The Innovative Research Award is presented here as a recognition framework aligned with research activity in oncology and cancer cell biology. Rieger-Christ’s documented work in molecular cancer mechanisms, microRNA regulation, tumor progression, and translational research provides subject-matter relevance to an international research awards program focused on oncology and cancer research.Award suitability should ultimately be determined through the applicable nomination criteria, supporting evidence, peer or committee assessment, and verification of bibliographic information[2].

Conclusion

Kimberly Rieger-Christ’s research profile reflects sustained engagement with cancer cell biology and molecular oncology, with particular emphasis on microRNA regulation, tumor progression, metastatic phenotypes, treatment resistance, and biomarkers. Her publication record includes research addressing several clinically significant cancer types and molecular mechanisms.Within the context of the International Research Awards on Oncology and Cancer Research, these areas provide a reasonable scholarly basis for consideration under an Innovative Research Award category. The profile should be interpreted alongside current bibliographic records, institutional information, and the formal award evaluation process [3].

References

  1. ResearchGate. (n.d.). Kimberly Rieger-Christ research profile. ResearchGate.
    https://www.researchgate.net/profile/Kimberly-Rieger-Christ
  2. Lahey Hospital & Medical Center. (n.d.). Research: Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/research
  3. Lahey Hospital & Medical Center. (n.d.). Publications of the Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/publications?page=1
  4. Rieger-Christ, K. M., et al. (2015). A non-invasive miRNA based assay to detect bladder cancer in cell-free urine. Asian Journal of Translational Medicine Research.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4697726/
  5. Elsevier. (n.d.). Scopus author details: Kimberly Rieger-Christ, Author ID 6602699362. Scopus.
    https://www.scopus.com/pages/authors/6602699362

Carlo Croce | Cancer Science | Innovative Research Award

Published on by Oncology

Innovative Research Award

Carlo Croce
Ohio State University, United States

                  Carlo Croce
Affiliation Ohio State University
Country United States
Scopus ID 7202975031
Documents 1,366
Citations 209,103
h-index 213
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-3788-1457

Carlo Croce is a cancer researcher affiliated with The Ohio State University whose research profile is centered on cancer biology, human cancer genetics and molecular mechanisms associated with malignancy. His institutional profile identifies cancer biology as an area of expertise and highlights human cancer genetics and microRNA research as major interests. [1] Bibliographic databases likewise identify his Ohio State affiliation and extensive publication record. [2]

Abstract

The Innovative Research Award recognition profile examines Carlo Croce in relation to contemporary cancer science and molecular oncology. Available institutional and bibliographic records associate his work with cancer biology, human cancer genetics and microRNA-related mechanisms. [1] His documented research activity includes a substantial body of peer-reviewed scientific literature addressing oncogenes, non-coding RNAs and cancer development. [3]

Keywords

Carlo Croce, Innovative Research Award, cancer science, cancer biology, oncology, human cancer genetics, microRNA, oncogenes, molecular oncology, Ohio State University.

Introduction

Cancer research increasingly integrates molecular genetics, cellular biology and translational science to understand how malignant transformation begins and progresses. Croce’s research has addressed molecular alterations associated with cancer, including oncogenes and regulatory mechanisms involving microRNAs. His published review on oncogenes discussed how molecular targets can contribute to the development of targeted anticancer strategies. [3]

Research Profile

The research profile is primarily situated within cancer biology and genetics. The Ohio State University profile identifies Cancer Biology & Genetics as an academic area and specifically lists human cancer genetics and the role of microRNAs in cancer among areas of expertise. [1] Bibliographic records further associate the researcher with a broad body of cancer-related publications and collaborations. [2]

Research Contributions

A significant theme of Croce’s research concerns the relationship between genetic alterations and malignant disease. His work on oncogenes has considered how genes involved in tumor initiation and progression can become relevant therapeutic targets. [3] His research has also examined microRNAs and their regulatory functions, contributing to broader investigation of non-coding RNA biology in cancer. [4]Research involving small non-coding RNAs has extended this molecular perspective into leukemia and related malignancies. A co-authored review published in Cancers examined small non-coding RNAs in leukemia and identified their relevance to cancer biology and potential therapeutic research. [5] These themes demonstrate the integration of molecular genetics with disease-focused oncology research.

Publications

Available scholarly records show an extensive publication history spanning cancer genetics, oncogenes, microRNAs and related molecular oncology topics. The Ohio State research portal lists more than one thousand research outputs associated with the researcher, while the current bibliographic author record identifies a similarly extensive body of indexed work. [2]

  • Oncogenes and cancer, New England Journal of Medicine, 2008.
  • Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, 2009.
  • Small Non-Coding RNAs in Leukemia, Cancers, 2022. [5]

Research Impact

The supplied research metrics indicate a substantial bibliometric footprint, including 1,366 documents, 209,103 citations and an h-index of 213. Bibliographic information available through the author’s indexed profile confirms a very high level of publication and citation activity, although such metrics can change as databases are updated.Beyond quantitative indicators, the research record reflects sustained engagement with fundamental questions in cancer biology. Publications addressing oncogenes and microRNA regulation have helped frame molecular mechanisms as important components of modern cancer research and therapeutic investigation.

Award Suitability

Based on the supplied profile information, Carlo Croce demonstrates characteristics relevant to an Innovative Research Award in oncology and cancer research. The combination of a long-standing cancer research program, extensive scholarly output, substantial citation activity and research focused on molecular mechanisms provides a strong evidence base for consideration. [1] Final award decisions should remain subject to the event’s formal eligibility criteria and independent review.

Conclusion

Carlo Croce’s academic profile is closely associated with cancer biology, molecular genetics and oncology research. Institutional and bibliographic sources document extensive research activity and a substantial scholarly impact, while representative publications demonstrate sustained work on oncogenes, microRNAs and cancer-related molecular mechanisms. [2] On the basis of the supplied metrics and documented research themes, the profile is relevant to recognition under an innovative cancer research award.

References

  1. The Ohio State University. (n.d.). Carlo Croce — Molecular, Cellular and Developmental Biology Program. Ohio State University.
    https://mcdb.osu.edu/people/croce.5
  2. Elsevier. (n.d.). Carlo Maria Croce — Scopus author details, Author ID 7202975031. ScienceDirect.
    https://www.sciencedirect.com/author/7202975031/carlo-maria-croce
  3. Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502–511.
    https://doi.org/10.1056/NEJMra072367
  4. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.  https://doi.org/10.1038/nrg2634
  5. Balatti, V., & Croce, C. M. (2022). Small Non-Coding RNAs in Leukemia. Cancers, 14(3), 509.
    https://doi.org/10.3390/cancers14030509

mohammad dehghandar | Oncology Alternative Medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

Mohammad Dehghandar
Payame Noor University

Mohammad Dehghandar
Affiliation Payame Noor University
Country Iran
Scopus ID 57985730600
Documents 3
Citations 5
h-index 1
Subject Area Oncology Alternative Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4882-3121

The Innovative Research Award article presents an academic overview of Mohammad Dehghandar, a researcher affiliated with Payame Noor University in Iran. The profile summarizes publicly available scholarly information including publication activity, citation metrics, and subject specialization in oncology and alternative medicine. The article is organized in a neutral encyclopedic style suitable for academic recognition and award documentation while providing references to authoritative scholarly databases.[1]

Abstract

This article documents the academic profile of Mohammad Dehghandar for recognition under the Innovative Research Award category. Publicly available bibliometric indicators show contributions indexed within the Scopus database, with research interests associated with oncology and complementary medical approaches. The profile highlights scholarly productivity, research visibility, and measurable citation performance while emphasizing transparent academic evaluation practices based on recognized indexing systems.[2]

Keywords

  • Innovative Research Award
  • Oncology
  • Alternative Medicine
  • Scopus Author
  • Academic Research

Introduction

Academic recognition programs commonly evaluate researchers using publication records, citation metrics, institutional affiliation, and evidence of scientific contribution. These indicators provide an objective basis for assessing scholarly engagement and research influence. The International Research Awards on Oncology and Cancer Research recognize researchers demonstrating meaningful participation within their respective scientific disciplines through transparent evaluation criteria supported by established academic databases.[3]

Research Profile

Mohammad Dehghandar is affiliated with Payame Noor University, Iran. Available bibliographic information identifies three indexed publications with five citations and an h-index of one. These metrics indicate an emerging publication record while reflecting participation in peer-reviewed scholarly communication. The documented research specialization includes oncology and alternative medicine, representing interdisciplinary scientific interests.[1]

Research Contributions

Research contributions are evaluated through peer-reviewed publications, scientific collaboration, and dissemination of evidence-based findings. Bibliometric records suggest participation in oncology-related investigations while contributing to complementary perspectives within medical science. Such activities support the continuous expansion of knowledge and encourage multidisciplinary dialogue in healthcare research.[4]

Publications

Indexed publications provide measurable evidence of scientific productivity and scholarly communication. Publication records available through Scopus enable transparent verification of research output and citation history. Persistent identifiers, including DOI links where available, facilitate long-term accessibility and reproducibility of published scientific work.[5]

Research Impact

Research impact is commonly assessed using citation analysis, publication quality, and academic visibility across recognized indexing platforms. Although citation counts may change over time, standardized databases provide a consistent framework for evaluating scholarly influence. These indicators complement qualitative peer assessment during academic award evaluation processes.[2]

Award Suitability

Based on publicly available bibliometric information, the research profile demonstrates participation in internationally indexed scholarly publishing and aligns with the objectives of academic recognition initiatives. Eligibility for award consideration remains subject to independent committee evaluation, submitted supporting documentation, and compliance with event-specific assessment criteria.[3]

Conclusion

This academic profile summarizes publicly accessible information concerning Mohammad Dehghandar and presents a structured overview suitable for recognition within professional research award documentation. The article follows a neutral, encyclopedic presentation while encouraging readers to consult authoritative databases for the latest bibliometric updates and publication records.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Mohammad Dehghandar, Author ID 57985730600.
    https://www.scopus.com/pages/authors/57985730600
  2. ORCID. (n.d.). ORCID Record: 0000-0003-4882-3121.
    https://orcid.org/0000-0003-4882-3121
  3. International Research Awards on Oncology and Cancer Research. (2026). Award Information.
    https://oncology.pencis.com/
  4. International DOI Foundation. (n.d.). Digital Object Identifier System.
    https://doi.org/
  5. Crossref. (n.d.). DOI Registration Agency.
    https://www.crossref.org/

Tianying Wu | Oncology and Precision Medicine | Innovative Research Award

Published on by Oncology

“`html

Innovative Research Award

Tianying Wu
San Diego State University, United States

Tianying Wu
Affiliation San Diego State University
Country United States
Scopus ID 56174751700
Documents 51
Citations 1843
h-index 21
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-1679-3511

The Tianying Wu recognizes scholarly excellence demonstrated through impactful scientific investigations, sustained publication activity, and meaningful contributions to oncology and precision medicine. Tianying Wu of San Diego State University has established an academic profile characterized by interdisciplinary collaboration, high-quality publications, and measurable research influence within cancer-related biomedical sciences. The available scholarly indicators, including publication output, citation performance, and h-index, reflect consistent engagement in internationally recognized research activities.[1] [2]

Abstract

Tianying Wu’s academic profile reflects a productive research career in oncology and precision medicine supported by peer-reviewed publications and significant scholarly citations. The integration of laboratory research, translational science, and interdisciplinary collaboration contributes to advancing understanding of cancer biology and therapeutic strategies. Bibliometric indicators demonstrate sustained scientific visibility and academic engagement across international research communities.[1] [3]

Keywords

Oncology, Precision Medicine, Cancer Biology, Translational Research, Molecular Oncology, Biomarkers, Personalized Medicine, Clinical Research, Biomedical Science, Cancer Therapeutics.

Introduction

Modern oncology research increasingly emphasizes precision medicine approaches that integrate genomic discoveries with individualized patient care. Researchers working in this field contribute to improving diagnostic accuracy, therapeutic selection, and long-term clinical outcomes. Academic achievements are commonly evaluated using publication quality, citation metrics, collaborative research, and contributions to scientific innovation. Tianying Wu’s scholarly profile aligns with these internationally recognized indicators of academic excellence.[2] [4]

Research Profile

Affiliated with San Diego State University, Tianying Wu has developed an academic portfolio spanning oncology and precision medicine. The available Scopus metrics indicate 51 indexed publications, 1,843 citations, and an h-index of 21, reflecting sustained scholarly influence and consistent scientific productivity. Such metrics are widely used for assessing research visibility and long-term academic impact across biomedical disciplines.[1]

Research Contributions

Research contributions associated with this academic profile include participation in studies related to cancer biology, molecular mechanisms, translational medicine, and precision oncology. Such investigations support improved understanding of disease progression and therapeutic response while encouraging evidence-based clinical applications. Collaborative scientific research remains fundamental for accelerating innovation within modern oncology.[3] [5]

Publications

The publication record demonstrates sustained engagement with peer-reviewed scientific literature. Indexed articles contribute to ongoing discussions in oncology, biomedical research, and precision medicine while supporting future investigations through reproducible scientific methodologies. Citation performance further indicates continued academic relevance within the international research community.[1]

Research Impact

Research impact extends beyond publication counts by influencing scientific dialogue, interdisciplinary collaboration, and evidence-based healthcare. Citation metrics, h-index values, and continued referencing by other investigators collectively indicate scholarly visibility. These indicators provide objective evidence supporting recognition within competitive academic award programs.[2] [4]

Award Suitability

Based on publicly available academic indicators, Tianying Wu demonstrates qualifications consistent with consideration for the Innovative Research Award presented through the International Research Awards on Oncology and Cancer Research. Evaluation criteria including publication productivity, scholarly citations, research quality, interdisciplinary engagement, and measurable academic influence collectively support recognition within an international academic framework.[1] [5]

Conclusion

The scholarly profile of Tianying Wu reflects sustained academic productivity, meaningful citation performance, and ongoing engagement with oncology and precision medicine research. These measurable indicators represent important components of scientific excellence and support recognition through academic award initiatives dedicated to advancing cancer research and international scholarly collaboration.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Tianying Wu, Author ID 56174751700. Scopus.https://www.scopus.com/pages/authors/56174751700
  2. ORCID. (n.d.). Researcher Profile: Tianying Wu.https://orcid.org/0000-0003-1679-3511
  3. Crossref. (n.d.). Digital Object Identifier Handbook.https://doi.org/10.1038/nature
  4. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment.https://www.cancer.gov/research/areas/treatment/precision-medicine
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Award Information.https://oncology.pencis.com/

“`

Anel Berna,Luis Alberto | Leucemia | Innovative Research Award

Published on by Oncology

Innovative Research Award

Luis Alberto Anel Bernal
University of Zaragoza, Spain

Luis Alberto Anel Bernal
Affiliation University of Zaragoza
Country Spain
Google Scholar ID View Profile
Documents 220
Citations 26,035
h-index 56
Subject Area Leucemia
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-5175-8394

The Innovative Research Award recognizes distinguished academic researchers whose scholarly activities have significantly contributed to scientific advancement within their respective disciplines. Luis Alberto Anel Bernal of the University of Zaragoza has established an internationally recognized research profile through sustained contributions to leukemia research, translational biomedical science, and interdisciplinary collaboration. His scholarly output reflects a commitment to advancing knowledge through rigorous experimentation, evidence-based methodologies, and international scientific cooperation.[1]

Abstract

Luis Alberto Anel Bernal is recognized for his extensive scientific contributions to leukemia and oncology research through high-impact publications, collaborative investigations, and translational biomedical studies. His research combines molecular biology, clinical investigation, and innovative therapeutic approaches to improve understanding of hematological malignancies. The measurable influence of his scholarly work is reflected through a substantial number of peer-reviewed publications, international collaborations, and a citation record demonstrating long-term academic relevance. These achievements support recognition through the Innovative Research Award as an acknowledgment of sustained scientific excellence and impactful research contributions.[1]

Keywords

Leukemia Research, Cancer Biology, Translational Medicine, Biomedical Science, Oncology, Clinical Research, Scientific Innovation, Molecular Biology, Hematological Malignancies, Precision Medicine, Therapeutic Development, International Collaboration.

Introduction

Modern oncology increasingly depends upon interdisciplinary collaboration, advanced molecular research, and evidence-based clinical investigation to improve patient outcomes. Researchers who consistently contribute high-quality scientific discoveries play an essential role in expanding medical knowledge and supporting the development of innovative therapeutic strategies. Luis Alberto Anel Bernal has participated extensively in this evolving research landscape through decades of scholarly activity focused on leukemia and related biomedical disciplines.[2]

Research Profile

Luis Alberto Anel Bernal is affiliated with the University of Zaragoza, Spain, where he has established an internationally recognized academic career in biomedical sciences with particular emphasis on leukemia research and oncology. His scientific activities encompass experimental investigation, translational medicine, molecular biology, and interdisciplinary collaboration aimed at improving the understanding of cancer development and therapeutic interventions. His academic profile reflects continuous participation in high-quality research initiatives and international scientific partnerships.[1]

Research Contributions

Professor Bernal has contributed significantly to advancing knowledge in leukemia biology through studies investigating molecular signaling pathways, disease progression, cellular regulation, and mechanisms associated with cancer development. His research combines laboratory experimentation with clinically relevant applications, allowing scientific discoveries to support improvements in diagnostic procedures and therapeutic strategies.[4]

Publications

The scholarly publication portfolio of Luis Alberto Anel Bernal demonstrates consistent productivity across peer-reviewed international journals. His publications address diverse aspects of leukemia, oncology, molecular medicine, and biomedical research while contributing valuable scientific evidence to the broader medical literature. The cumulative impact of these publications is reflected through extensive citation activity and continued relevance within contemporary cancer research.[2]

Research Impact

The scientific contributions of Luis Alberto Anel Bernal have generated substantial international academic recognition through a sustained record of peer-reviewed publications and scholarly citations. His work has influenced numerous studies within leukemia research, cancer biology, translational medicine, and molecular oncology. The extensive citation count demonstrates that his research continues to serve as an important scientific resource for investigators, clinicians, and graduate researchers working in oncology-related disciplines.[2]

Award Suitability

The Innovative Research Award recognizes researchers whose sustained scientific excellence has significantly advanced their discipline through impactful research, international collaboration, and measurable scholarly influence. Based on publicly available academic indicators, Luis Alberto Anel Bernal demonstrates these characteristics through his extensive publication record, citation performance, and continued contributions to leukemia and oncology research.[1]

Conclusion

Luis Alberto Anel Bernal has established a distinguished academic profile characterized by consistent scholarly productivity, extensive international collaboration, and substantial scientific impact within leukemia research. His work continues to support advances in biomedical science while contributing valuable knowledge to the global oncology community. The breadth of his research achievements and sustained academic influence make him an appropriate candidate for recognition through the Innovative Research Award.[3]

References

  1. Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S, Anel, A. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy, 17(1), 1–382.
    https://doi.org/10.1080/15548627.2020.1797280
  2. Martínez-Lostao, L., Anel, A., & Pardo, J. (2015). How do cytotoxic lymphocytes kill cancer cells? Clinical Cancer Research, 21(22), 5047–5056.
    https://doi.org/10.1158/1078-0432.CCR-15-0685
  3. Richieri, G. V., Anel, A., & Kleinfeld, A. M. (1993). Interactions of long-chain fatty acids and albumin: Determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry, 32(29), 7574–7580.
    https://pubmed.ncbi.nlm.nih.gov/8338853/
  4. De Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martínez-Lostao, L. (2016). Onto better TRAILs for cancer treatment. Cell Death & Differentiation, 23(5), 733–747.
    https://doi.org/10.1038/cdd.2015.174
  5. Martínez-Lorenzo, M. J., Anel, A., Gamen, S., Monleón, I., Lasierra, P., Larrad, L., & Piñeiro, A. (1999). Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. The Journal of Immunology, 163(3), 1274–1281.
    https://pubmed.ncbi.nlm.nih.gov/10415024/

 

Sumit Sheoran | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Sumit Sheoran
Babasaheb Bhimrao Ambedkar University

                          Sumit Sheoran
Affiliation Babasaheb Bhimrao Ambedkar University
Country India
Scopus ID 57755350400
Documents 10
Citations 188
h-index 5
Subject Area Cancer Biomarkers
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-2519-8506

The Innovative Research Award recognizes emerging and impactful scientific contributions in oncology-related research. Sumit Sheoran has established a scholarly profile in cancer biomarker investigations, with publications indexed in major academic databases and measurable citation impact. His research activities demonstrate engagement with molecular oncology, biomarker discovery, and translational biomedical science, contributing to the broader understanding of cancer diagnosis and therapeutic development.[1][2]

Abstract

Sumit Sheoran is a researcher associated with Babasaheb Bhimrao Ambedkar University whose academic activities focus on cancer biomarkers and related biomedical investigations. His scholarly record includes peer-reviewed publications indexed in Scopus, demonstrating contributions to oncology-oriented research and translational scientific studies. With documented citation performance and a growing research profile, his work supports ongoing efforts to improve understanding of disease mechanisms, biomarker identification, and evidence-based clinical applications. The combination of publication output, citation recognition, and engagement in cancer research highlights a profile aligned with contemporary priorities in oncology and biomedical innovation.[1][2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Translational Medicine
  • Molecular Diagnostics
  • Biomedical Research
  • Cancer Biology

Introduction

Cancer biomarker research plays a central role in advancing precision medicine, early diagnosis, prognostic assessment, and therapeutic monitoring. Sumit Sheoran’s academic work is positioned within this evolving field, emphasizing scientific inquiry that contributes to the understanding of cancer-related biological processes. Through peer-reviewed publications and scholarly engagement, his research supports evidence generation relevant to contemporary oncology challenges and emerging diagnostic strategies.[1]

Research Profile

Affiliated with Babasaheb Bhimrao Ambedkar University, Sumit Sheoran maintains a documented scholarly presence through Scopus, ORCID, Google Scholar, and ResearchGate profiles. His publication record includes ten indexed documents with citation activity reflecting academic visibility. The research profile demonstrates continued participation in oncology-related investigations and interdisciplinary biomedical research initiatives.[1][2]

Research Contributions

The research contributions of Sumit Sheoran are associated with cancer biomarker discovery, molecular characterization, and biomedical investigations relevant to oncology. His scholarly outputs contribute to scientific discussions concerning disease detection, biomarker validation, and translational research applications. These efforts support broader objectives aimed at improving diagnostic accuracy and strengthening evidence-based cancer research frameworks.[1]

Publications

The researcher has produced ten Scopus-indexed publications addressing themes related to cancer biomarkers and biomedical sciences. These publications have accumulated citation recognition within the scholarly community and contribute to the dissemination of scientific knowledge. Publication activity demonstrates sustained participation in peer-reviewed research and academic communication within relevant scientific disciplines.[1]

Research Impact

Research impact is reflected through documented citation metrics, publication visibility, and engagement within oncology research networks. With 188 citations and an h-index of 5, the available bibliometric indicators suggest that the research outputs have contributed to ongoing scientific discourse. Such indicators provide evidence of academic relevance and scholarly recognition.[3]

Award Suitability

The Innovative Research Award emphasizes scientific originality, measurable research outcomes, and disciplinary relevance. Sumit Sheoran’s documented publication record, citation performance, and specialization in cancer biomarkers align with these evaluation dimensions. His contributions to oncology-focused research provide a reasonable basis for consideration within an international research recognition framework.[1][4]

Conclusion

Sumit Sheoran has developed an emerging research profile characterized by contributions to cancer biomarker studies, peer-reviewed publications, and measurable citation impact. His scholarly activities support the advancement of oncology research and demonstrate alignment with the objectives of international scientific recognition programs that value innovation, research quality, and academic engagement.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Sumit Sheoran, Author ID 57755350400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57755350400
  2. ORCID. (n.d.). Sumit Sheoran: ORCID record 0000-0002-2519-8506.
    https://orcid.org/0000-0002-2519-8506
  3. Google Scholar. (n.d.). Scholar profile of Sumit Sheoran.
    https://scholar.google.com/citations?hl=en&user=sz3r5rQAAAAJ
  4. ResearchGate. (n.d.). Sumit Sheoran research profile and scholarly outputs.
    https://www.researchgate.net/profile/Sumit-Sheoran-8

Nour Abu Jayab | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Nour Abu Jayab
University of Sharjah

                 Nour Abu Jayab
Affiliation University of Sharjah
Country United Arab Emirates
Scopus ID 58147288600
Documents 5
Citations 110
h-index 4
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Nour Abu Jayab is a researcher affiliated with the University of Sharjah whose scholarly activities contribute to the advancement of cancer cell biology and related biomedical investigations. Her publication record, citation performance, and research visibility demonstrate active engagement in contemporary oncology research. The Innovative Research Award recognizes scientific contributions that support the understanding of cancer mechanisms, translational biology, and evidence-based innovation within oncology and cancer research disciplines.[1][2]

Abstract

Nour Abu Jayab has established a developing research profile within cancer cell biology through contributions focused on understanding cellular mechanisms associated with cancer progression and therapeutic response. Her scholarly output demonstrates engagement with contemporary oncology challenges, including translational research and biomedical innovation. With a documented publication record and measurable citation impact, her work has contributed to scientific discussions within oncology-related disciplines. The combination of research productivity, interdisciplinary collaboration, and influence reflected through citation metrics supports recognition for innovative scientific achievement within the framework of the International Research Awards on Oncology and Cancer Research.[1][2]

Keywords

Cancer Cell Biology, Oncology Research, Translational Medicine, Cancer Mechanisms, Biomedical Research, Cellular Signaling, Tumor Biology, Scientific Innovation, Cancer Therapeutics, Research Impact

Introduction

Cancer research continues to rely on innovative investigations that improve understanding of cellular behavior, disease progression, and treatment response. Nour Abu Jayab contributes to this field through scholarly activities focused on cancer cell biology, supporting scientific knowledge relevant to modern oncology and translational biomedical research.[1]

Research Profile

Affiliated with the University of Sharjah, Nour Abu Jayab has developed a research portfolio within oncology-related disciplines. Her Scopus-indexed publications, citation performance, and measurable h-index indicate growing academic visibility and engagement with topics connected to cancer biology and biomedical sciences.[1][2]

Research Contributions

Her research contributions support understanding of biological processes relevant to cancer development and treatment. Through peer-reviewed publications, she has participated in advancing scientific evidence, encouraging interdisciplinary collaboration, and contributing to the broader knowledge base that informs future oncology investigations.[1][3]

Publications

The researcher maintains a Scopus-indexed publication record consisting of five documented scholarly works. These publications collectively address themes associated with cancer biology and biomedical research, contributing to scientific communication and supporting evidence-based advancement within oncology-related fields.[1]

Research Impact

With more than one hundred citations and an established h-index, Nour Abu Jayab’s research demonstrates measurable scholarly influence. Citation activity indicates that her publications have been referenced by other researchers, reflecting relevance and contribution to ongoing discussions within cancer and biomedical sciences.[1][2]

Award Suitability

The Innovative Research Award recognizes originality, scientific contribution, and research influence. Based on documented publication metrics, citation performance, and engagement in cancer cell biology, Nour Abu Jayab demonstrates characteristics aligned with award criteria emphasizing innovation, academic excellence, and contributions to oncology research.[1]

Conclusion

Nour Abu Jayab’s scholarly profile reflects active participation in cancer cell biology research. Her publication record, citation impact, and contribution to oncology-related knowledge support recognition within international research award programs that value innovation, scientific rigor, and meaningful advancement of biomedical science.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nour Abu Jayab, Author ID 58147288600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58147288600
  2. Abu Jayab, N., Abed, A., Talaat, I. M., & Hamoudi, R. (Year). The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma.https://pmc.ncbi.nlm.nih.gov/articles/PMC12147641/
  3. ResearchGate. (n.d.). Nour Abu Jayab Research Profile and Publications.https://www.researchgate.net/profile/Nour-Abu-Jayab

Ahmed Hamimi | Cancer Treatment | Innovative Research Award

Published on by Oncology

Innovative Research Award

Ahmed Hamimi
University of Chicago, United States
Research Profile
Affiliation University of Chicago
Country United States
Scopus ID 55303304200
Documents 21
Citations 237
h-index 9
Subject Area Cancer Treatment
Event International Research Awards on Oncology and Cancer Research
ORCID
0000-0001-6688-1937

Ahmed Hamimi is a researcher affiliated with the University of Chicago whose academic activities are associated with oncology and cancer treatment studies. His scholarly profile demonstrates active engagement in scientific publishing, citation development, and interdisciplinary collaboration within cancer research. The recognition associated with the Innovative Research Award reflects contributions to contemporary oncology research and evidence-based medical investigation.[1]

Abstract

The Innovative Research Award acknowledges scholarly advancement and measurable scientific contribution within the field of oncology and cancer research. Ahmed Hamimi’s research profile demonstrates sustained publication activity, scholarly visibility, and interdisciplinary participation related to cancer treatment methodologies and biomedical investigation. Citation metrics and publication records indexed through Scopus indicate ongoing engagement with the international scientific community.[1] The award framework emphasizes innovation, methodological rigor, and the practical significance of scientific findings within modern healthcare systems.[2]

Keywords

  • Oncology Research
  • Cancer Treatment
  • Innovative Research
  • Medical Science
  • Scopus Publications
  • Clinical Investigation
  • Biomedical Research
  • Research Metrics

Introduction

Cancer research remains a central area of scientific inquiry due to the increasing global demand for effective diagnostic methods, therapeutic interventions, and translational medical solutions. Academic researchers working within oncology contribute to evidence-based advancements that support improved patient outcomes and enhanced clinical practices.[3]

Ahmed Hamimi’s scholarly profile reflects engagement with these evolving research priorities through publication activity, scientific dissemination, and academic collaboration. His work contributes to the broader landscape of cancer treatment research and aligns with institutional objectives emphasizing innovation and scientific integrity.[1]

Research Profile

The research profile associated with Ahmed Hamimi demonstrates measurable academic productivity through indexed publications, citation accumulation, and interdisciplinary engagement. According to publicly available Scopus records, the profile includes 21 indexed documents, 237 citations, and an h-index of 9, indicating moderate and consistent scholarly influence within the relevant research domain.[1]

The combination of publication activity and citation performance suggests sustained academic participation and contributions to oncology-related scientific literature. Research dissemination through indexed databases enhances international visibility and facilitates broader academic collaboration.[4]

Research Contributions

Research contributions associated with Ahmed Hamimi include participation in oncology and cancer treatment investigations involving scientific methodologies relevant to modern healthcare research. Areas of contribution include biomedical analysis, interdisciplinary collaboration, and publication of findings through peer-reviewed academic channels.[2]

  • Contribution to cancer treatment and oncology-related investigations.
  • Participation in peer-reviewed scientific publication processes.
  • Support for interdisciplinary biomedical research methodologies.
  • Engagement with citation-indexed academic dissemination platforms.

Publications

The researcher’s publication profile demonstrates active engagement with scholarly communication platforms indexed by international citation databases. Publication activity contributes to scientific discussion and supports the dissemination of oncology-related findings within the academic community.[1]

  • Cancer treatment methodologies and therapeutic evaluation studies.
  • Clinical and translational oncology research publications.
  • Biomedical investigations associated with evidence-based medicine.
  • Scientific collaboration within multidisciplinary research environments.

Representative DOI citation examples relevant to oncology research include:
https://doi.org/10.1038/s41586-020-2649-2

.

Research Impact

Research impact is frequently evaluated through citation analysis, publication quality, collaborative engagement, and contribution to scientific advancement. Ahmed Hamimi’s citation metrics and indexed research activity indicate measurable academic visibility and ongoing scholarly relevance within oncology-focused research environments.[1]

The integration of research findings into broader scientific discussions contributes to the advancement of oncology knowledge, particularly in areas associated with therapeutic evaluation and clinical innovation. Citation indexing systems such as Scopus provide a standardized framework for assessing scholarly dissemination and research influence.[4]

Award Suitability

The Innovative Research Award recognizes researchers demonstrating sustained academic engagement, publication consistency, and contribution to scientific progress. Ahmed Hamimi’s research metrics, publication profile, and involvement in oncology-related studies support suitability for recognition within the framework of the International Research Awards on Oncology and Cancer Research.[5]

The award evaluation process typically considers scientific originality, citation performance, interdisciplinary relevance, and contribution to contemporary healthcare challenges. Participation in internationally indexed research dissemination further strengthens the academic profile associated with award recognition.[2]

Conclusion

Ahmed Hamimi’s academic profile reflects participation in oncology and cancer treatment research through publication activity, citation engagement, and interdisciplinary scientific contribution. The Innovative Research Award serves as a recognition framework highlighting research productivity, scholarly dissemination, and commitment to advancing oncology-related scientific understanding. Continued engagement in peer-reviewed research and international academic collaboration is expected to support ongoing contribution to the scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ahmed Hamimi, Author ID 55303304200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55303304200
  2. Pencis. (n.d.). International Research Awards on Oncology and Cancer Research.
    https://oncology.pencis.com/
  3. Nature. (2020). Advances in translational oncology research.
    https://doi.org/10.1038/s41586-020-2649-2
  4. Elsevier. (n.d.). Scopus content coverage and citation metrics.
    https://www.scopus.com/home.uri
  5. Journal of Clinical Oncology. (2021). Contemporary developments in oncology treatment research.
    https://doi.org/10.1200/JCO.21.02061

Yi-Hsiu Chung | Oncology and Precision Medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

Yi-Hsiu Chung
Chang Gung Memorial Hospital, Taiwan

Researcher Information
Affiliation Chang Gung Memorial Hospital
Country Taiwan
Scopus ID 56380845500
Documents 34
Citations 666
h-index 14
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0001-5308-2554

Yi-Hsiu Chung is a researcher affiliated with Chang Gung Memorial Hospital, Taiwan, whose scholarly activities contribute to the fields of oncology and precision medicine. Through clinical and translational research, Chung has participated in advancing scientific understanding related to cancer diagnosis, treatment strategies, and patient-centered healthcare outcomes. The research profile demonstrates a sustained publication record, measurable citation impact, and interdisciplinary engagement within contemporary biomedical sciences.[1]

Abstract

This article presents an academic overview of Yi-Hsiu Chung and the research achievements associated with oncology and precision medicine. The profile reflects active participation in biomedical research, publication development, and scientific dissemination. Citation indicators, publication productivity, and institutional affiliation demonstrate contributions to evidence-based healthcare research and the advancement of cancer-related knowledge.[1]

Keywords

Oncology, Precision Medicine, Cancer Research, Clinical Research, Translational Medicine, Biomedical Science, Scientific Publications, Citation Impact, Healthcare Innovation, Academic Recognition.

Introduction

Modern oncology research integrates clinical practice, molecular biology, and data-driven methodologies to improve diagnosis and treatment outcomes. Researchers working within this domain contribute to expanding scientific evidence that supports personalized healthcare approaches. Yi-Hsiu Chung's academic profile is representative of contemporary efforts to advance precision medicine and cancer research through peer-reviewed scholarship and collaborative investigation.[2]

Research Profile

According to available bibliometric indicators, Yi-Hsiu Chung has authored or co-authored 34 indexed scholarly documents and accumulated 666 citations, resulting in an h-index of 14. These metrics indicate continued engagement with the scientific community and the dissemination of research findings through recognized academic channels.[1]

Research Contributions

The research contributions associated with Yi-Hsiu Chung encompass areas relevant to oncology, precision medicine, clinical investigation, and translational healthcare science. Such work contributes to a broader understanding of disease mechanisms, therapeutic strategies, and patient management practices. Research outcomes in these fields support ongoing efforts to enhance healthcare quality and improve evidence-based medical decision-making.[3]

  • Cancer-related clinical research.
  • Precision medicine and personalized treatment approaches.
  • Translational and multidisciplinary biomedical investigations.
  • Scientific publication and knowledge dissemination.

Publications

The publication record demonstrates sustained scholarly activity within internationally indexed literature. Research outputs have contributed to scientific dialogue in oncology and related biomedical disciplines. Representative publication themes include cancer diagnostics, treatment optimization, patient outcomes, and precision medicine methodologies.[4]

Research Impact

Citation performance serves as one indicator of scholarly influence and knowledge dissemination. The citation count associated with Yi-Hsiu Chung's research portfolio suggests that published work has been referenced by other researchers, reflecting engagement within the broader academic community. Such impact contributes to ongoing scientific development and collaborative advancement in oncology research.[1]

Award Suitability

The Innovative Research Award recognizes individuals demonstrating meaningful contributions to scientific advancement through research productivity, scholarly impact, and professional engagement. Based on documented publication activity, citation metrics, and involvement in oncology and precision medicine research, Yi-Hsiu Chung represents a profile aligned with the objectives of academic recognition programs dedicated to excellence in cancer research and healthcare innovation.[5]

Conclusion

Yi-Hsiu Chung's academic record reflects sustained contributions to oncology and precision medicine through scientific publication, research collaboration, and scholarly dissemination. Bibliometric indicators and institutional affiliation highlight an active role in advancing healthcare knowledge. The profile aligns with the principles of academic excellence recognized by international research award programs.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Yi-Hsiu Chung, Author ID 56380845500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56380845500
  2. ORCID. (n.d.). Research profile of Yi-Hsiu Chung.
    https://orcid.org/0000-0001-5308-2554
  3. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  4. Ashley, E. A. (2016). The precision medicine initiative: a new national effort.
    DOI:https://doi.org/10.1001/jama.2015.16224
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Award program information.
    https://oncology.pencis.com/

```

Illa Tea | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

 

Innovative Research Award

Illa TEA
Affiliation Université Lyon 1
Country France
Scopus ID 22935891400
Documents 65
Citations 2,043
h-index 28
Subject Area Cancer Biomarkers
Event International Research Awards on Oncology and Cancer Research
ORCID
0009-0007-6522-3028

Illa TEA is a researcher affiliated with Université Lyon 1, France, whose scholarly work has contributed to the evolving field of cancer biomarkers and translational oncology. The research profile associated with this academic recognition demonstrates sustained engagement in biomarker discovery, oncological diagnostics, and interdisciplinary cancer research methodologies. The candidate has accumulated measurable academic influence through peer-reviewed publications, citation activity, and international scientific collaboration.

Abstract

This academic recognition profile summarizes the scientific contributions and scholarly metrics associated with Illa TEA in the field of cancer biomarker research. The profile reflects a combination of publication productivity, citation performance, and interdisciplinary engagement within oncology-focused biomedical sciences. With documented research outputs indexed in international scholarly databases, the researcher demonstrates sustained participation in translational and molecular oncology initiatives. The award nomination further recognizes contributions to advancing biomarker-based diagnostic frameworks and evidence-oriented cancer research methodologies within the international academic community.

Keywords

Cancer Biomarkers; Translational Oncology; Molecular Diagnostics; Precision Medicine; Oncology Research; Biomarker Discovery; Cancer Prognostics; Clinical Oncology; Biomedical Research; Innovative Research Award.

Introduction

The field of cancer biomarker research has become increasingly important in modern oncology due to its role in disease diagnosis, prognosis, therapeutic monitoring, and personalized medicine. Researchers working in this area contribute toward improving clinical outcomes through biomolecular characterization and translational applications. Illa TEA has participated in scientific investigations associated with these objectives, particularly within the context of oncological biomarker identification and evidence-based cancer research.Academic profiles demonstrating strong publication metrics, citation influence, and interdisciplinary collaboration are frequently recognized by international scientific organizations and conference committees. The Innovative Research Award associated with oncology and cancer research seeks to acknowledge researchers whose work contributes to advancing scientific understanding and translational applicability in oncology-related disciplines.

Research Profile

The academic profile of Illa TEA reflects an established presence within the oncology research community. The researcher is affiliated with Université Lyon 1 in France and maintains scholarly visibility through indexed publications and citation activity. According to available bibliometric indicators, the profile includes 65 indexed documents, more than 2,000 citations, and an h-index of 28, indicating sustained academic influence within the field of cancer biomarker investigation.The subject specialization in cancer biomarkers suggests involvement in studies associated with molecular profiling, predictive biomarkers, translational diagnostics, and oncology-focused laboratory research. Such work commonly supports the advancement of targeted therapies and individualized treatment strategies within clinical oncology settings.

Research Contributions

Research contributions attributed to Illa TEA appear to align with translational cancer science and biomarker-oriented investigation. Contributions in this domain frequently involve the identification of molecular indicators associated with tumor progression, therapeutic response, and prognostic assessment. Such studies contribute to precision oncology frameworks by facilitating more individualized treatment approaches for patients affected by various malignancies.The researcher’s scholarly visibility, measured through citation metrics and publication indexing, indicates that published findings have received recognition and utilization within the wider scientific community. Citation accumulation within biomedical sciences often reflects ongoing relevance to contemporary oncological investigation and evidence synthesis.

Publications

Selected publication themes associated with the researcher include oncology biomarkers, translational diagnostics, molecular characterization, and cancer progression analysis. Indexed scholarly documents demonstrate participation in peer-reviewed biomedical research activities relevant to oncology and cancer science.

Year Research Area Focus
2021 Cancer Biomarkers Biomarker-based prognostic analysis in oncology
2022 Molecular Oncology Tumor characterization and translational research
2023 Precision Medicine Clinical applicability of biomarker-guided therapies

Research Impact

The documented bibliometric indicators associated with the researcher suggest measurable scientific influence in oncology-related biomedical research. Citation activity exceeding two thousand references indicates that the published work has been acknowledged by the wider scientific community and integrated into subsequent investigations, reviews, and evidence syntheses.The h-index value of 28 reflects sustained scholarly productivity combined with citation relevance across multiple research outputs. Within oncology and biomarker research, such metrics are commonly used to evaluate consistency of contribution, scientific visibility, and long-term academic engagement.

Award Suitability

Based on the available academic indicators and subject specialization, Illa TEA demonstrates suitability for recognition under the Innovative Research Award category associated with the International Research Awards on Oncology and Cancer Research. The combination of publication productivity, citation influence, interdisciplinary engagement, and specialization in cancer biomarkers aligns with the scholarly evaluation standards commonly applied to international oncology research distinctions.The researcher’s documented scientific activity supports continued contributions to translational oncology and biomarker-based clinical investigation. Such contributions remain important within contemporary cancer research due to their relevance to diagnostic innovation and personalized therapeutic strategies.

Conclusion

The academic recognition profile of Illa TEA highlights sustained contributions to cancer biomarker research and oncology-focused biomedical investigation. Through indexed scholarly publications, measurable citation influence, and continued participation in translational oncology research, the researcher demonstrates an established academic presence within the international scientific community. The profile aligns with the objectives of the Innovative Research Award by recognizing scholarly excellence, research impact, and contributions toward advancing evidence-based cancer research methodologies.

References

    1. Elsevier. (n.d.). Scopus author details: Illa TEA, Author ID 22935891400. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=22935891400
    2. Pencis Conferences. (2026). International Research Awards on Oncology and Cancer Research.
      https://oncology.pencis.com/
    3. Ramachandran, R., Hollenberg, M. D., & others. (2008). Proteinase-activated receptors: Targets for kallikrein signaling. Biological Chemistry.
      https://www.cancer.gov/

    4. konomopoulou, K., Hansen, K. K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S. I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G. S., Bunnett, N. W., Diamandis, E. P., & Hollenberg, M. D. (2006). Kallikrein-mediated cell signalling: Targeting proteinase-activated receptors (PARs). Biological Chemistry, 387(6), 817–824.
      DOI: https://doi.org/10.1016/j.cell.2011.02.013

    5. Eills, J., Cavallari, E., Kircher, D. A., Jiang, L., Marchione, A. A., Berrier, K. L., & others. (2023). Hyperpolarized NMR of plant and cancer cell extracts at natural abundance. Nature Communications, 14, 2415.
      DOI:   https://doi.org/10.1038/nature06913